Caleb Bates, Ph.D., is a trusted advisor and partner with emerging and established companies, developing patent portfolios that support their growth strategies by protecting their valuable intellectual property and maximizing loss of exclusivity. Whether his clients have a drug on the market, aim to bring a drug to market, partner development with another company, or position themselves for acquisition, Caleb provides tailored, forward-thinking strategies that set his clients up for success.
Caleb manages the worldwide prosecution strategy for several pre-clinical and clinical-stage biopharmaceutical companies, including portfolios with hundreds of filings across more than 45 jurisdictions.
In addition to his extensive experience in U.S. and international patent prosecution, Caleb routinely counsels clients in licensing, buy- and sell-side due diligence, and freedom-to-operate and patentability analyses. Throughout his career, Caleb has developed patent portfolios that have generated over $12 billion in deal value.
Caleb enjoys educating clients and others on best practices for and current topics in intellectual property via seminars, webinars, and continuing legal education.
Caleb received his Ph.D. in medicinal chemistry from the University of Michigan, where his graduate research involved the design, synthesis, and mechanistic evaluation of small molecule modulators of eukaryotic gene transcription. When not in the office, Caleb enjoys hiking in the mountains of Northern California with his dogs, Oberon and Juniper.
Recognitions & awards
U.S. Rising Star - Intellectual Property
LMG Life Sciences
Life Sciences Star
LMG Life Sciences
Barrister’s Club, Bar Association of San Francisco, IP Section Executive Committee (2018-Present)